已發表論文
發表論文
2022.03.31
- Huang CE, Wu YY, Hsu CC, Chen YJ, Tsou HY, Li CP, Lai YH, Lu CH, Chen PT, Chen CC* (corresponding author). Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms. J Formos Med Assoc 2021;120:863-873. (SCI；IF=3.282；Medicine, General and Internal 53/169)
- Verstovsek S, Chen CC, Egyed M, Ellis M, Fox L, Goh YT, Gupta V, Harrison C, Kiladjian JJ, Lazaroiu MC, Mead A, McLornan D, McMullin MF, Oh ST, Perkins A, Platzbecker U, Scheid C, Vannucchi A, Yoon SS, Kowalski MM, Mesa RA. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol 2021;17:1449-1458. (SCI；IF=3.404；Oncology 160/242)
- Hsu CC, Chen YJ, Huang CE, Wu YY, Wang MC, Pei SN, Liao CK, Lu CH, Chen PT, Tsou HY, Li CP, Chuang WH, Chuang CK, Yang CY, Lai YH, Lin YH, Chen CC* (corresponding author). Molecular Heterogeneity Unraveled by Single-Cell Transcriptomics in Patients with Essential Thrombocythemia. Br J Haematol 2020;188:707-722. (SCI；IF=6.998；Hematology 12/76)
- Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol 2019;37:240-252. (SCI；IF=5.271；Hematology 22/76)
- Hsu CC, Huang CE, Wu YY, Chen YY, Lung J, Leu YW, Li CP, Tsou HY, Chuang WH, Lu CH, Chen CC* (corresponding author). Quantitative Competitive Allele-Specific TaqMan Duplex PCR (QCAST-Duplex PCR) Assay: A Refined Method For Highly Sensitive And Specific Detection Of JAK2V617F Mutant Allele Burdens. Haematologica 2018;103:e454. (SCI；IF=9.941；Hematology 8/76)
- Wang MC, Huang CE, Lin MH, Yang YH, Lu CH, Chen PT, Wu YY, Tsou HY, Hsu CC, Chen CC* (corresponding author). Impacts of demographic and laboratory parameters on key hematological indices in an adult population of southern Taiwan: A cohort study. PLoS One. 2018;13:e0201708. (SCI；IF=3.240；Multidisciplinary Sciences 26/73)
- Chen CC, You JY, Lung J, Huang CE, Chen YY, Leu YW, Ho HY, Li CP, Lu CH, Lee KD, Hsu CC, and Gau JP. Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms. Haematologica 2017;102:509-18. (SCI；IF=9.941；Hematology 8/76)
- Chen CC, Chiu CC, Lee KD, Hsu CC, Chen HC, Huang Tim HM, Hsiao SH, and Leu YW. JAK2V617F influences epigenomic changes in myeloproliferative neoplasms. Biochem Biophys Res Commun. 2017;494:470-6. (SCI；IF=3.575; Biochemistry & Molecular Biology 173/298)
- Chen CC, Hsu CC, Huang CE, Chen YY, Lung J, Ho HY, Li CP, Lee JD. Enhanced risk for specific somatic myeloproliferative neoplastic mutations in patients with stroke. Curr Neurovasc Res 2017;14:222-31. (SCI；IF=1.990; Neurosciences; Ranking 233/273)
- Huang CE , Chen YY , Liu JL, Ho HY, Li CP, Chen CC* (corresponding author). JAK2V617F mutation in immune thrombocytopenia. Thromb Res 2016;144:149-51. (SCI；IF=3.944；Hematology 30/76)
- Chen CC* (first and corresponding author), Chen YY, Huang CE. Cryptococcal Meningoencephalitis Associated with Long-term Use of Ruxolitinib Ann Hematol 2016;95:361-2. (SCI；IF=3.673；Hematology 35/76)
- Chen YY , Huang CE, Lee KD, Chen CC* (corresponding author). Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan. Hematology 2016;21:3-9. (SCI；IF=2.269；Hematology 60/76)
- Gau JP, Chen CC* (corresponding author), Chou YH, Liu CJ, Yu YB, Hsiao LT, Liu JH, Hsu HC, Chiou TJ, Chen PM, Tzeng CH. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation. Blood Cells Mol Dis 2015;55:36-9. (SCI；IF=3.039；Hematology 47/76)
- Chen CC, Gau JP, Chou HJ, You JY, Huang CE, Chen YY, Lung J, Chou YS, Leu YW, Lu CH, Lee KD, Tsai YH. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol 2014;93:2029-36. (SCI；IF=3.673；Hematology 35/76)
- Shen CH, Chen YY, Huang CE, Chen CC* (corresponding author). Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol 2014;93:1075–6. (SCI；IF=3.673；Hematology 35/76)
- Shih LY, Kuo MC, Kuo CY, Lin TH, Bai LY, Chen TY, Wang MC, Lin TL, Lan YJ, Chen CC,Yang Y, Hsiao PC, Lai CL, Chang CH, Lin TH. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure. Leuk Res. 2013; 37:43-9.